Thursday, 10th February 34th Lorne Cancer Conference 2022

• Is Nuclear Factor Kappa B a Viable and Druggable Target in Prostate Cancer? - Christopher Sweeney
• Next-generation therapies for ER+ breast cancer: investing in the biology from the molecular to the patient-level - Ciara Metcalfe
• Ovarian carcinosarcoma genomics and preclinical models enable identification novel mechanisms of action of eribulin on N-MYC and the mevalonate pathway - Holly Barker
• Single cell expression profiling of prostate cancer xenografts reveals divergent mechanisms of resistance to androgen deprivation co-exist within individual tumours - David L Goode
• The Androgen Receptor as a Therapeutic Target in Breast Cancer - Theresa Hickey

• Identification of new therapeutic approaches to overcome resistance to cancer immunotherapy - Jane Oliaro
• Boosting cellular immunogenicity to combat metastatic breast and prostate cancers - Belinda Parker
• Functional heterogeneity of tissue-resident lymphocytes - Laura Mackay
• Interferon epsilon limits ovarian cancer metastasis via tumour-extrinsic mechanisms - Nicole Campbell
• Inhibition of the NPY signalling axis as a novel therapeutic option in Pancreatic Cancer. - Cecilia Chambers
• Combined targeting strategy of gp130/STAT3 inhibitors with chemotherapy and SMAC mimetics potently enhances pro-apoptotic responses in colorectal cancer - Rhynelle Dmello
• High throughput cell morphology-based drug screen in breast and prostate cancer reveals novel AR agonists - Amy Dwyer
• The molecular profile of secondary meningiomas in survivors of childhood non-central nervous system cancers - David D Eisenstat
• Hungry for more: Increased oxidative metabolism and TCA cycle activity in prostate cancer - Gio Fidelito
• Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression. - Brian Gabrielli
• Uncovering subtype specific intra-tumoural heterogeneity in brain cancer - Sarah A Best

The peer-review process at EMBO Press - towards optimized publishing and open science

Daniel Klimmeck, PhD, Senior Editor, The EMBO Journal

Meyerhofstr. 1, 60117 Heidelberg, d.klimmeck@embojournal.org

The peer reviewed research paper remains the main conduit for the exchange of research discoveries. With the diversification and growth of global research, publishing in selected journals and citation metrics are increasingly employed as surrogates for quality in research assessment. Consequently, the pressure to publish in a handful of journals has increased, putting the peer review system under strain.  I will discuss EMBO’s organizational aim and activities and provide an overview of the five journals published by EMBO as an academic organization (The EMBO Journal/EMBO Reports/MSB/EMBO Mol Medicine/ Life Science Alliance). Importantly, the Editorial Process as run at The EMBO Journal will be explained, thus outlining function and daily routines of scientific editors. Finally, I will present a number of policies that EMBO has implemented under its 'transparent peer review' scheme and that ensure a fast, fair and informed editorial process.

Daniel received his PhD in 2008 with work on ion channel signaling in sensory neurons in the laboratory of Stephan Frings at the University of Heidelberg, Germany. As a postdoc, he focused on the molecular characterization of cancer and haematopoietic stem cells with Andreas Trumpp at the German Cancer Research Center (DKFZ) and Jeroen Krijgsveld at EMBL. Daniel joined The EMBO Journal in 2015, where he is responsible for stem cells, ageing, metabolism and cancer, among other subject areas. Further, Daniel serves as reviewing editor at the journal-agnostic peer-review platform Review Commons.

• Novel EGFRvIII-specific murine CAR T cells eliminate glioblastoma tumours and provides an opportunity for further engineering - Rebecca C Abbott
• Developing novel pre-clinical models for mucinous ovarian cancer - Suad M Abdirahman
• An integrative genomics approach identifies MCL-1 as a therapeutic target in childhood high-grade gliomas   - Shazia S A Adjumain
• MKK7 loss drives resistance to combination endocrine therapy + CDK4/6 inhibition in ER+ breast cancer - Sarah Alexandrou
• Characterising the adaptive starvation response in melanoma cells treated with targeted therapies. - Arwa Alkaraki
• Improved BRAF/MEK inhibitor efficacy using a high-fat diet in male mice - Shaghayegh Arabi
• DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and in response to immunotherapy. - Louise Baldwin
• Nucleic acid aptamers as ‘chemical antibodies’ for the histochemical detection of cancer stem cells and rapid, microfluidic isolation of circulating tumour cells - Michelle L Bauer
• MLL1-induced β-catenin activity promotes colon tumorigenesis - Jia Bian
• Repair of spontaneous methyl cytosine DNA damage - Rebecca A Bilardi
• Determining the essential functions of distinct pro-survival BCL-2 family members by using gene-swap mice - Kerstin Brinkmann
• Transcriptomic and chromatin profiling of mouse mammary epithelial cell identity - Kara Britt
• Subcellular localization of JNK in metastatic cancer - Antonia L Cadell
• Role of Clusterin (CLU)-Expressing Cells in Promoting Chemoresistance in Colorectal Cancer   - Wing Hei Chan
• Genome-wide CRISPR/Cas9 knockout screens to understand the mechanism of action of the anti-cancer agent APR-246 - Tianwei Chen
• Does knocking-out a tetraspanin gene in cancer cells affect the expression of other tetraspanins? - Rocky Chowdhury
• Senescence reprogramming in ER+ breast cancer - Olivia O Ciampa
• Determining the role of mutant Dnmt3a in the development of haematopoietic malignancies - Amali Cooray
• Exploring new treatment options for mucinous ovarian carcinoma  - Olivia Craig
• Oncogenic Notch1 can replace the Lmo2/Lyl1 stem cell program in murine Lmo2-induced T-cell acute lymphoblastic leukemia - David J Curtis
• Early detection of melanoma using circulating tumour-specific antibodies - Jessica Da Gama Duarte
• Targeting epithelial-to-mesenchymal transition in ovarian carcinosarcoma - Genevieve Dall
• Whole genome CRISPR/Cas9 screening to understand resistance to BH3-mimetic drugs in lymphoma - Sarah Diepstraten
• Tissue remodeling supports tumour signalling heterogeneity and shapes tumour cell invasion in glioblastoma - Marija MD Dinevska
•  Detection of circulating tumour DNA in high-risk paediatric acute lymphoblastic leukaemia (ALL) - Louise Doculara
• Reprogramming Diffuse Midline Glioma (DMG) with Histone H3K27M Mutation - the role of DLX homeobox genes in regulation of oligodendroglial progenitor cell (OPC) differentiation - David D Eisenstat
• Characterising the potential tumour suppressor function of caspase-3 in human colorectal cancer - Meg J Elliott
• Modelling colorectal cancer using patient-derived organoid lines to personalise cancer medicine - Rebekah Engel
• Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers - Allegra Freelander
• Targeted transcriptome and KRAS mutation analysis improve the diagnostic performance of EUS-FNA biopsies in pancreatic cancer - Hugh Gao
• Modelling chemotherapy-induced apoptosis to improve response in high-risk neuroblastoma - Jeremy Han
• Defining the heterogeneity of cellular function during growth and therapy resistance in colorectal cancer - Sara Hlavca
• Targeting mutant HLA-bound cancer peptide demonstrated in vivo efficacy in delaying tumour growth in a low mutational burden aggressive ovarian cancer  - Gwo Yaw Ho
• Understanding and overcoming resistance to ribosome-targeting therapy in human acute myeloid leukaemia - Xinran Huang
• Loss of mismatch repair protein MLH1 reduces tumour burden in mouse model of gastric cancer - Anne Huber
• Discovery of novel drug combinations for metastatic colorectal cancer - Eun-Jung In
• Predictive biomarkers of recurrence may not be useful for deescalating treatment of breast ductal carcinoma in situ due to de novo ipsilateral breast carcinoma development - Tanjina Kader
• Understanding the regulation of the pro-apoptotic BH3-only protein PUMA to enhance the efficacy of cancer treatment - Deeksha Kaloni
• Not so fast: Why somatic testing in cancer patients doesn’t tell the whole story - Anchit Khanna
• Developing CRISPR base editing applications to accurately identify tumour promoting mutations in lymphomagenesis - Christina Koenig
• Analysis of FOS transcription factor orthologue in zebrafish melanoma - khadizatul Kubra
• EZH2 Abundance Regulated by UHRF1/UBE2L6/UBR4 Ubiquitin System is the Potential Therapeutic Target to Trigger Pigmented Phenotype in Melanoma - Gamze Kuser Abali
• Characterising the role of ARRDC3 as a regulator of P53-mediated apoptosis - John (Eddie) E La Marca
• Setting the scene for ER+ syngeneic tumour cell lines - Maria Lambouras
• Characterisation of the effect of PRMT5 inhibitor (GSK3266595) on Pancreatic Ductal Adenocarcinoma - Michael KC Lee
• Revolutionizing Gene Delivery from Design to Therapy - Thomas Leung
• Novel switchable mutant p53 mouse strains to investigate p53 gain-of-function effects in tumours - Elizabeth Lieschke
• Inhibiting PRMT5: A Novel Target for the Treatment of Melanoma  - Lydia Lim
• Integrated single cell analysis of chemical and genetic HDAC inhibition to inform precision medicine for neuroblastoma - Monica Phimmachanh
• Detection and Quantification of Nanoparticle-Induced Intracellular ROS in HT1080 Fibrosarcoma Cell Lines by Scanning Laser Confocal Microscopy - Maria John Newton Amaldoss

• Lipoteichoic acid also contributes to oral cancer cell proliferation - Rajdeep Chakraborty
• Inhibition of the dipeptidyl peptidase 4 enzyme family enhances CD8 T-cell recruitment and activates caspase 1 in a murine model of primary hepatocellular carcinoma - Mark D Gorrell
• When drug resistance becomes a vulnerability: exploiting the NRF2-MRP1-GSH axis to improve treatment response of lung cancer - Kimberley Hanssen
• De novo design of CRISPR-Cas13b enables the silencing of tumour RNAs with single-base precision    - Wenxin Hu
• cellCounts: highly efficient and accurate scRNA-seq read mapping and quantification - Yang Liao
• Fuling inhibits endometrial cancer invasion in vitro. - Sidra Khan
• Deciphering the role of SULF1 in cancer stem cell function - Laura Rangel
• Pdcsm-cancer: using graph-based signatures to identify small molecules with anticancer properties - Raghad Al Jarf
• Eribulin normalises tumour vasculature by inducing mural cell maturation - Bo He
• Mechanisms regulating polyadenylation of the lncRNA RPPH1 in breast cancer cells - Kiarna Kavanagh-Beck
• Characterisation of epithelial-to-mesenchymal transition in ovarian carcinosarcoma - Anthony Hadla
• LGR5 CAR-T cells: A novel treatment against high grade serous ovarian cancer - Jady WANQI Wang
• Characterization of AML in TP53-deficient golden Syrian hamsters - Robert Cormier
• Cystic fibrosis, CFTR and colorectal cancer - Robert Cormier
• Unravelling the links between cGAS and mitotic cell death - Enaam Alghamdi
• Bioinformatics prediction of microRNAs targeting PTEN and its pseudogene, PTENp1 - Glena Travis
• Quantitating PTEN and PTENp1 pseudogene expression: Potential for future cancer therapy - Glena Travis
• Collateral damage in the COVID era: Perforated rectal cancer causing Fournier’s gangrene - Charbel Karam
• Fibrolamellar hepatocellular carcinoma with paraneoplastic neuropsychiatric manifestations - Charbel CK Karam
• Streptococcus pneumoniae potently kill mesothelioma cells in a strain dependent manner - Hui Juin Shak
• Whole Genome Sequencing of rare gynaecological cancers  - Ratana Lim
• Survival of patients with multiple primary cancers - Amelia Ang
• Perforated colon adenocarcinoma manifesting as necrotising fasciitis - Charbel Karam
• Developing and Surviving Multiple Primary Cancers - Kristy Shield-Artin
• Targeting MYCN to enhance anti-tumour immunity in Ovarian Cancer - Gowri Irgam
• Epithelial-Mesenchymal Transition drivers of metastatic cSCC: potential therapeutic targets  - Benjamin Genenger
• The origin and contribution of cancer-associated fibroblasts in colorectal carcinogenesis - Susan L Woods
• Immune Regulation Of The Premetastatic Niche Formation In Triple-negative Breast Cancer - Laura Rodriguez de la Fuente
• Ion channels as novel therapeutic targets in diffuse midline glioma - Abbie Francis
• Identifying the function and signalling role of ErbB4 in High-Grade Gliomas - Jamie-Lee Pitcher
• ZNF384-rearranged B-cell acute lymphoblastic leukaemia is potentiated by recurrent genomic lesions susceptible to therapeutic targeting - Barbara J McClure
• HMGN1 expression predisposes Down Syndrome patients to develop P2RY8-CRLF2 acute lymphoblastic leukaemia - Elyse Page
• Understanding breast cancer patients’ response to neoadjuvant chemotherapy at single-cell resolution - Niantao Deng
• Uncovering dynamic changes in Medulloblastoma associated vasculature in zebrafish - Elysse Morris
• SUPER-NEXT: employing comprehensive clinical genomics for cancer of unknown primary. - Richard J Rebello
• Identifying the expression of voltage-gated calcium channel subunits in High-grade gliomas - Sara Rezaeiravesh
• Uncovering the role of regulatory T cells in the regression of cutaneous Squamous Cell Carcinoma (cSCC) - Shoaib Anwaar
• Autoantibodies as prognostic biomarkers for cutaneous melanoma - Desiree Sexauer
• HIVE scRNAseq: The complete solution from single cells to libraries for RNAseq, with integrated sample storage - Matthew Brockman
• The anti-cancer agent APR-246 can kill malignant cells through several distinct mechanisms independent of mutant TP53   - Zilu Wang
• Stromal mediators of immune dysfunction in triple negative breast cancer - Julia Chen
• Investigation of metastatic-castration resistant prostate cancer heterogeneity using single-cell technologies - Raisa Hasan
• Optimising immunotherapy for paediatric medulloblastoma by enhancing brain-resident myeloid cells - Zahra Abbas
• Establishing tumour organoid models of cancer of unknown primary enables in vitro testing of genomically informed and individualised drug treatments - Atara Posner
• BRCA1 D11q isoform expression impacts PARP inhibitor responses in ovarian carcinoma patient derived xenografts - Ksenija Nesic
• Desmoglein-2 expression by multiple myeloma is an independent predictor of poor prognosis  - Claudine S Bonder
• Comprehensive assessment of homologous recombination deficiency by whole genome transcriptome sequencing for personalised cancer management - Layla Zhu
• Building a cellular atlas of localised luminal breast cancers - Beata M Kiedik
• TGF-β and CIS inhibition synergistically enhance NK cell anti-tumor immunity - Gustavo Rossi
• Establishment of clinical curation principles for whole genome and transcriptome sequencing of cancers of unknown primary - Camilla B Mitchell
• Evaluate the role of EZH1/EZH2 in tumorigenesis of DIPG cells - Motahhareh (Flora) Tourchi
• An experimental perspective of the Digital Spatial Profiling (DSP) and Visium technologies - Tony Wang
• Rescuing Immune Control of Bone-metastatic Breast Cancer with Type I interferon Modulators - Miriam Fuentes
• Single-cell RNA sequencing identifies potential common components of the dormant tumour cell niche across metastatic tissues - James T Smith
• Single-cell RNAseq analysis of IL11-dependent pathways in Triple Negative Breast Cancer - Sarah Bennett
• Repurposing bortezomib for improved treatment of melanoma by exploiting immunogenic cell death - Nikolas Haass
• Phenotypic melanoma heterogeneity is regulated through cell-matrix interaction-dependent changes in tumour microarchitecture - Nikolas K Haass
• Multi-omic and spatial dissection of immunotherapy response groups in non-small cell lung cancer (NSCLC) - Arutha Kulasinghe